Risque d'événements cardiovasculaires majeurs dans les troubles inflammatoires à médiation immunitaire sous l'effet de produits biologiques et de petites molécules : Méta-analyse en réseau
CClin Gastroenterol Hepatol 2023;22:961-970.e12
The results of this study show that anti-IL-12/23, JAK inhibitors, and anti-TNF-α were associated with slightly higher risk of MACE compared with placebo. The risk was no different between biologic treatments, and the magnitude of risk did not differ between IMID type.